Table 1

Baseline characteristics

VariablesAll (n=134)PTR (n=67)PR (n=67)
Female sex, n (%)74 (55)35 (52)39 (58)
Age, year68.3 (9.0)68.4 (8.7)68.2 (9.4)
Body mass index, kg/m225.7 (5.8)25.5 (5.0)25.9 (6.4)
FEV1, % predicted33.1 (9.4)32.6 (10.3)33.7 (8.4)
FEV1/FVC, %43.3 (11.2)43.9 (11.3)42.7 (11.1)
GOLD I/II/III/IV, %0/0/61/390/0/55/450/0/67/33
A/B/C/D, %2/34/4/605/34/3/580/33/4/63
LTOT, n (%)20 (15)11 (16)9 (13)
SpO2 at rest, %94.6 (2.8)94.6 (2.4)94.8 (3.1)
MRC 1/2/3/4/5, n0/2/65/50/170/2/30/27/80/0/35/23/9
Smoking status, n (%)
 Never3 (2)2 (3)1 (1)
 Former99 (75)51 (79)48 (72)
 Current30 (23)12 (18)18 (27)
Pack-year history, mean (SD)43.5 (20.2)42.4 (23.1)44.5 (17.3)
BODE index points, median (IQR)5.0 (4–6)5.0 (4–7)5.0 (4–6)
Charlson Comorbidity Index 1/2/≥3, (%)40/37/2345/40/1534/33/33
Exacerbations, previous 12 month, (median, IQR)2 (0–3)2 (0–4)2 (1–3)
Current medication, n (%)
 SABA112 (84)56 (84)56 (84)
 SABA + SAMA11 (8)6 (9)5 (7)
 LABA2 (1)1 (1)1 (1)
 LAMA3 (2)2 (3)1 (1)
 LABA + LAMA24 (18)12 (18)12 (18)
 LABA + ICS8 (6)5 (7)3 (5)
 LABA + LAMA + ICS93 (69)45 (67)48 (71)
 Oral steroids2 (1)2 (3)0 (0)
Walking aid, walker/other, n (%)27/18 (34)14/9 (34)13/9 (33)
Highest 6MWD, metre327.3 (102.8)322.3 (108.3)332.3 (97.5)
Highest 30sec-STS, repetitions9.8 (4.3)9.9 (4.7)9.6 (3.8)
Physical activity level*
 Daily step count, steps3091 (2161)2779 (1966)3422 (2335)
 Time sedentary, min1205 (133)1244 (121)1164 (134)
 Time active, min235 (133)196 (121)276 (134)
CAT, score20.1 (7.0)19.8 (7.3)20.4 (6.6)
HADS, score
 HADS-anxiety6.3 (3.5)6.8 (3.8)5.9 (3.1)
 HADS-depression4.3 (3.0)4.5 (2.)4.1 (3.1)
EQ-5D, VAS score52.7 (19.2)51.5 (19.4)53.9 (19.1)
EQ-5D, index score0.68 (0.16)0.66 (0.20)0.70 (0.12)
CCQ, score
 Symptoms2.9 (1.2)2.8 (1.2)3.0 (1.2)
 Functional2.9 (1.2)2.8 (1.1)3.0 (1.3)
 Mental2.8 (1.4)2.8 (1.5)2.9 (1.4)
 Total2.8 (0.9)2.7 (0.9)2.9 (1.0)
  • Data are presented as mean (SD) except where otherwise indicated.

  • *ActivePAL triaxial accelerometer worn by in total 73 patients (PTR/PR: 37/36). Any statistically significant difference between PTR and PR denoted *p<0.05.

  • A/B/C/D, risk stratification, airflow obstruction, dyspnea and exercise capacity; BODE index, body mass index; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; EQ-5D, Euro-Qol 5-dimension; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; GOLD, Global initiative for Chronic Obstructive Lung Disease; HADS, Hospital Anxiety and Depression Score; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTOT, long-term oxygen therapy; MRC, Medical Research Council; 6MWD, 6 min walk distance; PR, pulmonary rehabilitation; PTR, pulmonary tele-rehabilitation; SABA, short-action β2-agonist; SAMA, short-acting muscarinic antagonist; 30-sec STS, 30 s sit-to-stand test; SpO2, arterial oxygen saturation as measured by pulse oximetry; VAS, Visual Analogue Scale.